Boston biotechnology company Soufflé Therapeutics announced a USD 135 million Series B on 13 October 2026, led by Juvia Group. The new financing follows its earlier USD 200 million Series A and should not be confused with that previous round. Led by CEO Amir Nashat, the company is developing technology intended to deliver RNA medicines to selected cell types beyond conventional delivery targets. Its REMEDY platform supports programmes addressing muscle and cardiovascular conditions. The funding will advance research and clinical development. Founder links include Robert Langer and Susan Langer. Therapeutic effectiveness and clinical outcomes remain matters for future evidence.
Soufflé Therapeutics raises USD 135 million for targeted RNA medicines
Juvia Group leads the Boston biotechnology company's Series B.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


